CXCL10 and type 1 diabetes mellitus: Elevated circulating FABP4 was observed in both adults[15] and children[47] with T1D, and was identified as a key regulator in ketoacidosis under T1D conditions.[48] The pathogenic FABP4‐CXCL10 axis identified in the present study is aligned with clinical findings showing significant induction of CXCL10 in the circulation and inflamed islets of recent‐onset T1D patients.[26, 36] CXCL10 not only enhances cytotoxic T cell recruitment but also promotes Th1 cell activation[34] and suppresses β cell proliferation,[35] thereby exacerbating T1D.